ArticleDiagnostics (Basel, Switzerland)2023
Urinary Metabolomic Analysis of Prostate Cancer by UPLC-FTMS and UPLC-Ion Trap MS
Article in Diagnostics (Basel, Switzerland), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- Urinary metabolomic signatures associated with early adverse events during volumetric modulated arc therapy for prostate cancer: A secondary analysis of a public dataset.Molecular and clinical oncology · 2026Article
- Latest Developments in Mass Spectrometry-Based Techniques for Metabolomics Analysis.Advances in experimental medicine and biology · 2026Review
- Metabolomics-Based Liquid Biopsy for Predicting Clinically Significant Prostate Cancer.Cancers · 2025Review
- Evaluating Differential Metabolic Profiles by Prostate Cancer Risk Among Prostate Cancer Patients.Metabolites · 2025Article
- The Fire Fighter Cancer Cohort Study: Protocol for a Longitudinal Occupational Cohort Study.JMIR research protocols · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Accumulative evidence suggests metabolic disorders correlate with prostate cancer. Metabolic profiling of urine allows the measurement of numerous metabolites simultaneously. This study set up a metabolomic platform consisting of UPLC-FTMS and UPLC-ion trap MS
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.